AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SCLX · NASDAQ · Drug Manufacturers - General

Scilex

Commercializes non-opioid treatments for acute and chronic pain.

$5.43

After-hours close−0.01 (−0.18%)

At close$5.44(−2.33%)

Something off on this page? Send us feedback.

Profile

Scilex Holding CompanySCLXHealth Care

Markets ZTlido, ELYXYB, and GLOPERBA while developing additional non-opioid pain-treatment candidates. The commercial portfolio combines topical and oral therapies with licensed product rights.

Markets ZTlido, a prescription lidocaine topical system for pain associated with post-herpetic neuralgia, alongside ELYXYB, a ready-to-use celecoxib oral solution for acute migraine in adults, and GLOPERBA, an oral colchicine solution for adult gout-flare prophylaxis. Its commercial activities center on the United States, with ELYXYB rights also covering Canada.

Combines commercialization of approved pain treatments with development of SEMDEXA (SP-102), SP-103, and SP-104. The portfolio has expanded through exclusive licensing and acquired rights, and the operating model depends on acquiring, developing, and commercializing non-opioid products for acute and chronic pain.

Company facts

CEOHenry Ji, Ph.D.

ListedNov 11, 2022

ExchangeNASDAQ

HeadquartersPalo Alto, CA

CountryUnited States

Employees34

CIK0001820190

ISINUS80880W2052

Key statistics

Market cap$46.1M

EPS (ttm)−$48.10

P/E (ttm)−0.1129

ROE189.8%

P/B−0.1214

P/S1.46

Dividend yield—

Beta1.12vs XLV 0.30

Year to date −58.4% · Average volume (30d) 65.3K

Analysts

No analyst consensus on record.

Earnings

EPS

Estimate−$0.18

Reported−$16.65−9,083.2%

Revenue

Estimate$16.0M

Reported$7.6M−52.2%

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 14, 2026Q2 FY26	−$0.18	−$16.65	−9,083.2%	$16.0M	$7.6M	−52.2%	+0.30%
May 20, 2026Q1 FY26	−$0.21	−$4.76	−2,166.5%	$15.0M	$8.6M	−42.6%	−1.34%
Apr 10, 2026Q1 FY26	−$0.29	−$4.60	−1,471.9%	$12.1M	$4.8M	−60.4%	−12.35%
Nov 14, 2025Q3 FY25	−$13.80	−$13.80	0.0%	$10.6M	$10.6M	0.0%	−12.32%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$5.0M	$9.9M	$10.6M	$4.8M	$8.6M	$7.6M
Gross profit	$3.6M	$6.6M	$7.2M	$591.0K	$4.2M	$1.1M
Operating income	−$27.9M	−$20.5M	−$186.5M	−$37.5M	−$32.2M	−$29.4M
Net income	−$26.1M	−$86.1M	−$257.2M	−$33.1M	−$43.3M	−$113.5M
Diluted EPS	−$2.26	−$7.42	−$22.17	−$3.00	−$6.28	−$16.65
Gross margin	72.3%	66.9%	68.5%	12.3%	48.4%	14.7%
Operating margin	-557.5%	-207.2%	-1,766.2%	-782.0%	-373.5%	-385.0%

Fiscal years (4-quarter sums)FY21 $31.3M · FY22 $38.0M · FY23 $46.7M · FY24 $56.6M · FY25 $30.3M

Balance sheet, Jun 30, 2026Cash & short-term investments $581.0K · Total debt $95.6M · Total assets $253.6M · Shareholders' equity −$308.3M

Dividends

No dividends on record.

Ownership

Institutions 8.28%Insiders —

Shares outstanding 8.49M · Float 7.50M · 88.3% free float

Insiders — no current Form 4 position.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Scilex Holding Co · 10 percent owner	244.45M		Form 4	Dec 30, 2025
SCLX Stock Acquisition JV LLC · 10 percent owner	958.3K		Form 4	Jul 7, 2026
Oramed Pharmaceuticals Inc.	732.7K	9.90%	13G	May 8, 2025
Vanguard Capital Management LLC	301.3K	3.55%	13F	Aug 13, 2026
BlackRock, Inc.	109.4K	1.29%	13F	Aug 7, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Apr 17, 2026	Henry Ji	director, officer: Exec Chair, CEO and President	−650,000	$1.20
Apr 16, 2026	Henry Ji	director, officer: Exec Chair, CEO and President	+3,250,000	$1.20
Apr 17, 2026	Stephen Hoi Ma	director, officer: CFO, COO and Secretary	+650,000	$1.20
Dec 30, 2025	Scilex Holding Co	10 percent owner	−9,657,300	$0.5394
Dec 29, 2025	Scilex Holding Co	10 percent owner	−7,310,984	$0.6555